Testing INBRX-109 for advanced solid tumors including sarcomas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a first-in-human, open-label, non-randomized phase 1 trial evaluating the safety and efficacy of INBRX-109, a recombinant humanized tetravalent antibody that targets the human death receptor 5 (DR5). The study involves three parts and includes patients with locally advanced or metastatic solid tumors, specifically Ewing sarcoma and colorectal adenocarcinoma. Participants will receive INBRX-109 in combination with standard chemotherapy agents such as Carboplatin, Cisplatin, Pemetrexed, and 5-fluorouracil. The trial aims to determine the maximum tolerated dose and assess the drug's potential therapeutic effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Males or females aged ≥12 to less than 85 years for Ewing sarcoma and 18 to less than 85 years of age for other tumors.
2. Part 3 combination therapy expansion tumor types:

   * Histologically confirmed Ewing sarcoma with a classical fusion: Patients with locally advanced or metastatic, unresectable, relapsed, or refractory disease who have received at least 1 but no more than 2 prior lines of systemic treatment with a preferred first line chemotherapy regimens.
   * Colorectal adenocarcinoma: Patients who have failed 1 (one) prior line of systemic therapy that did not include irinotecan.
   * Colorectal adenocarcinoma: Patients who have failed 2 but no more than 3 prior lines of systemic therapy and are FTD/TPI-naïve.
3. Measurable disease as defined by RECISTv1.1 (or modified RECIST for mesothelioma) criteria.
4. Adequate hematologic, coagulation, hepatic and renal function as defined per protocol.
5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1, or Karnofsky Performance Status score of ≥60, or Lansky Play-Performance Scale for Children score ≥60 (for patients less than 16 years).
6. Estimated life expectancy of at least 12 weeks.
7. Availability of archival tissue or fresh cancer biopsy are mandatory.

Exclusion Criteria:

1. Prior treatment with or exposure to DR5 agonists.
2. Receipt of any anticancer therapy (including investigational agents) within 4 weeks or within 5 half-lives prior to the first dose of study treatment. Exceptions per protocol.
3. Allergy or sensitivity to INBRX-109 or known allergies to CHO-produced antibodies.
4. Receipt of radiotherapy within 4 weeks prior to the first dose of study treatment, and liver-directed within 12 months prior to the first dose of study drug.
5. Subject has undergone allogeneic hematopoietic stem cell or bone marrow transplantation within the last 5 years. Exceptions per protocol.
6. Prior or concurrent malignancies. Exceptions per protocol.
7. Hematologic malignancies.
8. Symptomatic active primary CNS tumors, leptomeningeal disease, and CNS metastases. Exceptions per protocol. Patients with any evidence or history of multiple sclerosis (MS) or other demyelinating disorders are excluded.
9. Chronic liver diseases including fatty liver. Exception: Patients \< 45 years old with fatty liver disease may be accepted as long as adequate hepatic function as defined in the inclusion/exclusion criteria is confirmed.
10. Acute viral or toxic liver disease within 12 months prior to the first dose of study drug.
11. Evidence or history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection.
12. Known sensitivity or contraindications to the following drugs:

    * Ewing sarcoma: irinotecan or TMZ
    * colorectal adenocarcinoma: FU, leucovorin, irinotecan, bevacizumab or FTP/TPI
13. Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, cerebrovascular accident, or other acute uncontrolled heart disease less than 3 months prior to enrollment.
14. Acute, hemodynamically significant deep vein thrombosis or clinically significant pulmonary embolism not resolved or stable for at least 3 months prior to the start of study treatment.
15. Major surgery within 4 weeks prior to enrollment on this trial.
16. Systemic infection requiring antibiotics within 2 weeks prior to the first dose of study drug.
17. Other exclusion criteria per protocol.

Where it's running

• Precision NextGen Oncology and Research
  Beverly Hills, California, United States Recruiting
• City of Hope
  Duarte, California, United States Recruiting
• Valkyrie Clinical Trials
  Los Angeles, California, United States Recruiting
• Children's Hospital of Orange County-Rady Children's Health
  Orange, California, United States Recruiting
• University of California, San Francisco (UCSF)
  San Francisco, California, United States Recruiting
• Sarcoma Oncology Center
  Santa Monica, California, United States Recruiting

Study contacts

• Study coordinator: Study Director, -Inhibrx
• Email: clinicaltrials@inhibrx.com
• Phone: 858-500-7833

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BiP inhibitor BPR001-615 in colorectal adenocarcinoma

  This study tests whether the BiP inhibitor BPR001-615 can affect cancer cells from colorectal adenocarcinoma, in patients who will have surgical removal of their tumor at Nice University Hospital.

  Recruiting Centre Hospitalier Universitaire de Nice · Nice · NCT07813884

• VVD-133214 with Pembrolizumab in advanced colorectal cancer

  This study tests whether adding VVD-133214 to pembrolizumab helps people with advanced colorectal cancer better than pembrolizumab alone.

  Recruiting at 9 sites Phase 2 Vividion Therapeutics, Inc. · Tucson, Arizona and 121 other locations · NCT07811193

• Paclitaxel given inside the abdomen with systemic therapy for GI cancers with peritoneal spread

  This phase II study tests a combination of intraperitoneal and systemic chemotherapy (paclitaxel) in adults with digestive tract cancers that have spread to the peritoneum.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07795749

• Dynamic ProGRP Changes During Ewing Sarcoma Treatment

  This study tests whether changes in serum ProGRP levels over time reflect how well newly diagnosed Ewing sarcoma responds to treatment.

  Recruiting Peking University People's Hospital · Beijing · NCT07725783

• Breath test to help detect gastrointestinal cancers early

  A breath test that looks for signals in exhaled air to see if someone with gut cancer symptoms might have oesophageal, stomach, pancreatic, liver, or colorectal cancer and need urgent testing.

  Recruiting Imperial College London · Maidstone, Kent and 5 other locations · NCT07714538

• TLR9-based immunotherapy for peritoneal cancer with ascites

  This trial tests ACM-CpG injections into the abdomen to see if it’s safe and can help people with peritoneal metastases or malignant ascites from colorectal or appendiceal cancer.

  Recruiting Phase 1 Brown University · Providence, Rhode Island · NCT07658196

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.